Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Exemestane

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    124 result(s) found for: Exemestane. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2018-000693-30 Sponsor Protocol Number: 56UCS2017 Start Date*: 2019-11-25
    Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA
    Full Title: EXemestane in Progesterone and/or Estrogen receptor positive epithelial ovarian cancer. A Randomized phase III Trial, EXPERT.
    Medical condition: Women with confirmed high grade serous or endometrial epithelial ovarian cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-005752-16 Sponsor Protocol Number: CR0207-22 Start Date*: 2008-03-03
    Sponsor Name:Cancer Research UK
    Full Title: A Cancer Research UK randomised phase II trial of ATN-224 (copper binding agent) in combination with exemestane versus exemestane alone in post-menopausal women with recurrent or advanced, oestroge...
    Medical condition: recurrent or advanced oestrogen and/or progesterone receptor positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006198 Breast cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002365-63 Sponsor Protocol Number: GS-US-350-1937 Start Date*: 2017-04-19
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 1b Study Followed by an Open label, Parallel, Randomized Phase 2 Study Evaluating the Safety, Tolerability and Efficacy of GS-5829 in Combination with Exemestane or Fulvestrant Comparing wi...
    Medical condition: Advanced Estrogen Receptor Positive HER2-Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended) BE (Completed) GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-002717-35 Sponsor Protocol Number: MDV3100-12 Start Date*: 2013-11-26
    Sponsor Name:Medivation, Inc.
    Full Title: A Phase 2, Randomized, Double Blind, Placebo Controlled, Multicenter Study of Efficacy and Safety of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer That Is Estr...
    Medical condition: Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-005954-22 Sponsor Protocol Number: VEG108843 Start Date*: 2008-06-03
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A randomized, double-blind, placebo-controlled, multicenter Phase II study to compare the efficacy and tolerability of pazopanib administered in combination with exemestane versus exemestane plus p...
    Medical condition: Advanced or metastatic hormone receptor positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005461-13 Sponsor Protocol Number: CLEE011X2106 Start Date*: 2013-10-12
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A phase Ib/II trial of LEE011 in combination with everolimus (RAD001) and exemestane in the treatment of postmenopausal women with estrogen receptor positive Her2 negative locally advanced or metas...
    Medical condition: estrogen receptor positive, Her2- locally advanced or metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) DE (Completed) IT (Completed) GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-001698-89 Sponsor Protocol Number: Monet Start Date*: 2006-06-08
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: Molecular profiling of postmenopausal women with breast cancer on neoadjuvant exemestane or tamoxifen
    Medical condition: Early or locally advanced breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-000335-11 Sponsor Protocol Number: 8669-064 Start Date*: 2012-06-21
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 2 Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer ...
    Medical condition: ER positive, high proliferation breast
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) SE (Completed) CZ (Completed) BE (Completed) PT (Completed) DE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-002457-20 Sponsor Protocol Number: 3160A6-2206 Start Date*: 2008-12-30
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc.
    Full Title: "Estudio de fase 2, aleatorizado y abierto, de bosutinib administrado en combinación con exemestano frente a exemestano solo como tratamiento de segunda línea en mujeres posmenopáusicas con cáncer ...
    Medical condition: Cáncer de mama localmente avanzado o metastásico, RE+/RPg+/erbB2- en mujeres posmenopáusicas. Locally advanced or metastatic ER+/PgR+/Her2-breast cancer in post-menopausal women
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) BE (Completed) NL (Completed) FR (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003757-28 Sponsor Protocol Number: CRAD001Y2201 Start Date*: 2013-02-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A three-arm, randomized, open label, phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenopausal women with estrogen r...
    Medical condition: Estrogen receptor positive locally advanced or metastatic breast cancer in postmenopausal women
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) SE (Completed) GB (Completed) IE (Completed) DK (Completed) ES (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2013-004120-11 Sponsor Protocol Number: BOOG2013-06 Start Date*: 2014-03-17
    Sponsor Name:VU University Medical Center
    Full Title: PI3K pathway analysis in tumor tissue and circulating DNA to obtain further insight in the efficacy of everolimus when combined with exemestane. A side-study protocol attached to standard treatmen...
    Medical condition: Hormone receptor-positive advanced metastatic breast cancer in postmenopausal patients who have progressed on anastrozole or letrozole.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005063-16 Sponsor Protocol Number: IEO370 Start Date*: 2017-07-17
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: A randomized presurgical study with different schedules of exemestane in postmenopausal women with stage 0-II ER-positive breast cancer
    Medical condition: Postmenopausal ER positive breast cancer, waiting for surgery.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001921-34 Sponsor Protocol Number: C31001 Start Date*: 2015-04-30
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination With Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Bre...
    Medical condition: ER+/HER2- Advanced or Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10072737 Advanced breast cancer LLT
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-002114-23 Sponsor Protocol Number: BAY88-8223/17096 Start Date*: 2015-10-26
    Sponsor Name:Bayer HealthCare AG
    Full Title: A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with exemestane and everolimus versus placebo in combination with exemestane and everolimus whe...
    Medical condition: Metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) GB (Completed) ES (Completed) AT (Completed) CZ (Completed) NL (Completed) DE (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-006111-62 Sponsor Protocol Number: CRAD001JDE49 Start Date*: 2012-07-11
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A Phase IIIB, Multi-Center, Open Label Study For Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) in Combination Wi...
    Medical condition: The trial aims to evaluate the efficacy, safety, quality of life and health resources in postmenopausal women with hormone receptor positive breast cancer progressing following prior therapy with N...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-005573-21 Sponsor Protocol Number: A4021004 Start Date*: 2007-01-26
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A TWO-ARM RANDOMIZED OPEN LABEL PHASE 2 STUDY OF CP-751,871 IN COMBINATION WITH EXEMESTANE VERSUS EXEMESTANE ALONE AS FIRST LINE TREATMENT FOR POSTMENOPAUSAL PATIENTS WITH HORMONE RECEPTOR POSITIVE...
    Medical condition: Hormone receptor positive advanced breast cancer in postmenopausal women.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) NL (Temporarily Halted) GB (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-021220-10 Sponsor Protocol Number: D2610C00003 Start Date*: 2010-10-07
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised Double-blind Phase IIa Study (with Combination Safety Run-in) to Assess the Safety and Efficacy of AZD4547 in Combination with Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Pa...
    Medical condition: ER+ Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) FR (Completed) DE (Completed) HU (Completed) CZ (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001447-40 Sponsor Protocol Number: 28UCS2019 Start Date*: 2020-06-29
    Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA
    Full Title: Pilot Study of Daily Exemestane in Women with Complex Atypical Hyperplasia of the Endometrium / Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer
    Medical condition: Complex Atypical Hyperplasia of the Endometrium / Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer in post-menopausal women
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10014755 Endometrial hyperplasia PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-003065-17 Sponsor Protocol Number: CRAD001Y24135 Start Date*: 2013-05-16
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, phase II, single-arm study of everolimus in combination with letrozole in the treatment of postmenopausal women with estrogen receptor positive HER2 negative metastatic or locally ad...
    Medical condition: Estrogen receptor positive metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) FR (Completed) NL (Completed) PT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2014-004035-38 Sponsor Protocol Number: GIM16-FEVEX Start Date*: 2015-06-17
    Sponsor Name:CONSORZIO ONCOTECH
    Full Title: Fulvestrant ed EVerolimus più EXemestane nel carcinoma mammario metastatico” “Fulvestrant followed by everolimus plus exemestane vs examestane and everolimus followed by fulvestrant in postmenopaus...
    Medical condition: Hormone receptor positive (HR+) and human epidermal growth factor receptor type 2 negative (HER2-) locally advanced (LABC) or metastatic breast cancer (MBC)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 06:44:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA